Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07470489 | Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer | not yet recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07168785 | [18F]-AraG PET Imaging in LA HNSCC | not yet recruiting | Early Phase 1 | 5 | Indiana UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07241273 |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer(SELECT-FR) |
| not yet recruiting |
| N/A |
| 128 |
| UNICANCEROTHER |
| 1 |
| Jul 21, 2026 |
| clinicaltrials |
| NCT07064902 | Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer(MORALE-HN01) | not yet recruiting | Phase 1 / Phase 2 | 18 | Glycyx TherapeuticsINDUSTRY | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07692360 | Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma(IL6-OSCC) | not yet recruiting | — | 38 | University of PaviaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692906 | Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma | not yet recruiting | N/A | 80 | Xuelei Ma MDOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07578727 | A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma | not yet recruiting | N/A | 504 | Guangzhou Concord Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck(ZANACC) | not yet recruiting | Phase 2 | 51 | UNICANCEROTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Feng LiuOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07667296 | APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 826 | Aveta Biomics, Inc.INDUSTRY | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | not yet recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07674706 | Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers | not yet recruiting | N/A | 50 | National University Hospital, SingaporeOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07671573 | Integrated Early-CARE for Head & Neck Cancer.(i-CARE-HN) | not yet recruiting | N/A | 64 | Portuguese Oncology Institute, CoimbraOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07645846 | Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma(PANDA) | not yet recruiting | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07659678 | CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 90 | Washington University School of MedicineOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07661420 | 211At-MABG in Adults With Advanced Neuroendocrine Cancers | not yet recruiting | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07303283 | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 140 | Kai HuOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07628062 | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation | not yet recruiting | Phase 2 | 70 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07621146 | A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies(NET-COMPARE) | not yet recruiting | — | 51 | British Columbia Cancer AgencyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07584447 | Clinical Utility of Preoperative Thyroid GuidePx® Testing | not yet recruiting | — | 85 | University of CalgaryOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07616141 | Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma(NAET4-SNACC) | not yet recruiting | Phase 2 | 76 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07612293 | STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection | not yet recruiting | N/A | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06528353 | Blood Biomarkers Based Screening for HPV-driven OPC(SCREEN-HPV) | not yet recruiting | N/A | 10,000 | UNICANCEROTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT07589049 | Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study(GATEWAY) | not yet recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07563088 | SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma(SPARE-1st) | not yet recruiting | — | 200 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07579507 | Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma(HOPES) | not yet recruiting | N/A | 150 | Centre Leon BerardOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07279116 | ABY-029 Head & Neck Trial | not yet recruiting | Phase 1 | 24 | Dartmouth-Hitchcock Medical CenterOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT06899347 | The Role of Prophylactic Central Compartment Neck Dissection in the Management of 2 to 4 cm Papillary Thyroid Carcinoma(PRO-COMAND) | not yet recruiting | N/A | 392 | Leonardo RossiOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT07567742 | Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07565389 | Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma(AK112) | not yet recruiting | Phase 2 | 42 | National University Hospital, SingaporeOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07535567 | Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma(NimoBenSeq) | not yet recruiting | Phase 2 / Phase 3 | 386 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07554768 | Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC(RAIN-HNSCC) | not yet recruiting | Phase 2 | 36 | Chen ChunyanOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552883 | Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis(EPoRN) | not yet recruiting | N/A | 40 | Jiangxi Provincial Cancer HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07320820 | Quality of Life and Functional Outcomes in Laryngeal Cancer Patients(QoL in LSSC) | not yet recruiting | — | 120 | Saglik Bilimleri UniversitesiOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT07540390 | GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. | not yet recruiting | Phase 3 | 442 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545083 | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) | not yet recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT07536412 | Decision Aid Efficacy in Low Risk Thyroid Cancer | not yet recruiting | N/A | 34 | University of Maryland, BaltimoreOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07529769 | Artificial Intelligence for the Diagnosis of Oral Lesions(AID-OraL) | not yet recruiting | — | 5,000 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Apr 14, 2026 | clinicaltrials |
| NCT07529873 | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma(N'FORCE) | not yet recruiting | Phase 2 | 131 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 0 | Apr 14, 2026 | clinicaltrials |
| NCT07524413 | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 514 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07514767 | Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell Carcinoma(NOCANO) | not yet recruiting | Phase 2 | 60 | Prof. Lars Olaf CardellOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07512466 | Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations | not yet recruiting | N/A | 25 | Assiut UniversityOTHER | 0 | Apr 6, 2026 | clinicaltrials |
| NCT07507058 | Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma | not yet recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Apr 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 29, 2026source: clinicaltrials